Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Efonidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efonidipine SCHEMBL909287 | 1.00 | ABCB1 (0.95) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL27650540 | 0.99 | ABCB1 (0.96) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL1649423 | 0.98 | ABCB1 (0.93) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL349046 | 0.98 | ABCB1 (0.99) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL332377 | 0.98 | ABCB1 (0.99) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL49637 | 0.97 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL29410289 | 0.97 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL49638 | 0.97 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL29379054 | 0.97 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL28844127 | 0.96 | ABCB1 (0.97) | ABCB1LMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| EP-0893999-B1 | PROCESS FOR PRODUCING EFONIDIPINE HYDROCHLORIDE PREPARATIONS | NISSAN CHEMICAL IND LTD (JP) | 2002-09-11 | — | — | EP | claimed |
| US-6171599-B1 | HEAT TREATMENT; DIPPING AND IMPREGNATING WITH WATER CONTAINING SOLUTION; STEAMING; HYPOTENSIVE AGENTS; HIGH INTESTINAL ABSORBABILITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| JP-11246417-A | — | — | None | — | — | JP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024199025-A1 | SILYBIN-CONTAINING COMPOSITION | 江苏天士力帝益药业有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11773445-B1 | Diagnostic methods | GRIFFITH UNIVERSITY | 2023-10-03 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| EP-1680117-A2 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITY | Sanofi-Aventis (FR) | 2006-07-19 | — | — | EP | disclosed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| WO-2006042955-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006024777-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005046689-A2 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITY | SANOFI-AVENTIS (FR) | 2005-05-26 | — | — | WO | disclosed |
| EP-0893999-B1 | PROCESS FOR PRODUCING EFONIDIPINE HYDROCHLORIDE PREPARATIONS | NISSAN CHEMICAL IND LTD (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6171599-B1 | HEAT TREATMENT; DIPPING AND IMPREGNATING WITH WATER CONTAINING SOLUTION; STEAMING; HYPOTENSIVE AGENTS; HIGH INTESTINAL ABSORBABILITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| JP-H11246417-A | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETIC NEPHROPATHY | NISSAN CHEM IND LTD | 1999-09-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | ABCB1 978/4885LMNA 4522/4885CYP1A2 200/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ABCB1 1197/4885LMNA 3156/4885CYP1A2 1645/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ABCB1 5/4885LMNA 2176/4885CYP1A2 185/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ABCB1 5/4885LMNA 2176/4885CYP1A2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.